933 completed, 332 recruiting, 299 unknown, 249 terminated. 761 Phase 2, 623 Phase 1, 287 Not applicable, 168 Phase 3, 28 Early Phase 1.
Follow Ovarian Cancer: new trials by email Literature Review of Ovarian Cancer trials Research Report on Ovarian Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combined Program of Supervised Physical Exercise and Nutritional Counseling in Ovarian Cancer Patients on Frontline Maintenance Treatment With PARP Inhibitors Exercise and dietary recommendations - Ovarian Cancer | Not applicable | Not yet recruiting | Oncare Madrid | 32 | 2028-05-01 | 2026-10-08 |
| PITCH - Impacting Hereditary Cancer Testing Genetic testing education video - Ovarian Cancer, Genetic Testing | Not applicable | Not yet recruiting | Rachel Miller | 200 | 2027-04-01 | 2026-09-10 |
| NK521 in the Treatment of Advanced Solid Tumors NK521 Cell Injection - Hepatocellular Carcinoma (HCC), Ovarian Cancer | Early Phase 1 | Not yet recruiting | Base Therapeutics (Shanghai) Co., Ltd. | 18 | 2027-01-01 | 2026-09-30 |
| Study of Autologous, Metabolically Optimized, CD137+ Tumor-Infiltrating Lymphocytes Followed by Consolidative Oral Cyclophosphamide, Bevacizumab, and Pembrolizumab Fludarabine, Cyclophosphamide - Ovarian Cancer | Phase 2 | Not yet recruiting | Medical University of South Carolina | 20 | 2026-12-01 | 2026-07-22 |
| A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation LG00313112 - Ovarian Cancer, Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | LG Chem | 250 | 2026-12-01 | 2026-08-07 |
| Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1 INCB123667, Bevacizumab, Placebo - Ovarian Cancer | Phase 3 | Not yet recruiting | Incyte Corporation | 590 | 2026-12-01 | 2026-10-02 |
| Safety in Ovarian Cancer for Average-Risk Women - Analysis Blood-Based Ovarian Cancer Screening Test - Ovarian Cancer | Not applicable | Not yet recruiting | Mercy BioAnalytics, Inc. | 1750 | 2026-11-01 | 2026-10-16 |
| Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer Rina-S, Bevacizumab - Ovarian Cancer | Phase 3 | Not yet recruiting | Genmab | 602 | 2026-11-01 | 2026-10-05 |
| AI Analysis of CT Scans to Classify Ovarian Tumours as Benign, Borderline or Malignant Before Surgery Ovarian Cancer, Ovarian Tumor | Not yet recruiting | Catharina Ziekenhuis Eindhoven | 1300 | 2026-11-01 | 2026-10-20 | |
| Effects of Web-Based Ovarian Cancer Awareness Education on Women's Health Beliefs and Risk-Reducing Behaviors Web-Based Ovarian Cancer Awareness Education, General Reproductive Health Information - Ovarian Cancer | Not applicable | Not yet recruiting | Ege University | 82 | 2026-11-01 | 2026-10-22 |
| Trastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer Trastuzumab Rezetecan (SHR-A1811), Bevacizumab, Platinum-based chemotherapy - Ovarian Cancer, Fallopian Tube Cancers | Phase 2 | Not yet recruiting | Peking University Cancer Hospital & Institute | 53 | 2026-10-22 | 2026-10-01 |
| Dermatological Effects and Quality of Life in Oncology Patients skin barrier assessment - Breast Cancer, Ovarian Cancer | Not applicable | Not yet recruiting | European Institute of Oncology | 300 | 2026-10-12 | 2026-10-09 |
| A Phase 3 Study of Manganese-primed Immunochemotherapy in Patients With Advanced Ovarian Cancer Manganese Chloride, Nab-paclitaxel, Platinum chemotherapy - Ovarian Cancer | Phase 3 | Recruiting | Chinese PLA General Hospital | 120 | 2026-10-12 | 2026-09-16 |
| A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05) R-DXd, Bevacizumab, Carboplatin - Ovarian Cancer, Peritoneal Cancer | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 646 | 2026-10-07 | 2026-10-16 |
| Radiotherapy for Gynecologic Cancer With Up to 10 Active Metastatic Lesions Routine-care metastasis-directed radiotherapy - Cervical Cancer, Gynecologic Cancer | Recruiting | Affidea Nu-med Center of Oncological DIagnostics and Therapy | 500 | 2026-10-06 | 2026-10-23 | |
| Analysis of Breath Volatile Organic Compounds Using Mass Spectrometry Proton Transfer Reaction Mass Spectrometry Analysis - Pancreas Cancer, Hepatocellular Carcinoma | Not yet recruiting | University of Oklahoma | 2000 | 2026-10-01 | 2026-07-29 | |
| Stellate Ganglion Block and Dexmedetomidine for Postoperative Sleep in Women Undergoing Laparoscopic Gynecologic Surgery DEX 0.2 μg/kg/h., SGB, 0.9% Sodium Chloride (Placebo) - Uterine Fibroids (Leiomyoma), Adenomyosis of Uterus | Not applicable | Recruiting | Catherin Zhang | 100 | 2026-10-01 | 2026-10-06 |
| Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer Paclitaxel, Cisplatin, Bioferon - Ovarian Cancer | Phase 2 | Not yet recruiting | Kalinski, Pawel, MD, PhD | 28 | 2026-10-01 | 2026-10-13 |
| Contrast-enhanced Ultrasound Evaluation of Indeterminate Ovarian Lesions: Prospective Multicenter Study Contrast-Enhanced Ultrasound (CEUS) - Ovarian Cancer, Adnexal Lesion | Not applicable | Not yet recruiting | Thomas Jefferson University | 190 | 2026-10-01 | 2026-09-30 |
| A Study to Evaluate YF550 in Participants With Locally Advanced or Metastatic Solid Tumors. YF550 - Solid Tumor (Phase I), Ovarian Cancer | Phase 1 | Not yet recruiting | InventisBio Yiqi Beijing Limited | 204 | 2026-10-01 | 2026-10-26 |
Showing 20 of 2093. Sign in to see all of them.
Ovarian Neoplasms (2093) · Fallopian Tube Neoplasms (389) · Breast Neoplasms (380) · Carcinoma, Ovarian Epithelial (351) · Endometrial Neoplasms (249) · Uterine Cervical Neoplasms (199) · Colorectal Neoplasms (182) · Carcinoma, Non-Small-Cell Lung (179) · Pancreatic Neoplasms (172) · Neoplasms (162) · Lung Neoplasms (155) · Prostatic Neoplasms (142) · Stomach Neoplasms (139) · Sarcoma (120) · Melanoma (106)
Endocrine Gland Neoplasms (2093) · Female Urogenital Diseases (2093) · Female Urogenital Diseases and Pregnancy Complications (2093) · Genital Diseases (2093) · Gonadal Disorders (2093) · Urogenital Diseases (2093) · Adnexal Diseases (2092) · Endocrine System Diseases (2092) · Neoplasms by Site (2089) · Genital Diseases, Female (2088) · Urogenital Neoplasms (2084) · Genital Neoplasms, Female (2082) · Ovarian Diseases (2080) · Neoplasms (1931) · Neoplasms by Histologic Type (715)
Carboplatin (219) · Paclitaxel (219) · Bevacizumab (109) · Topotecan (68) · Gemcitabine (66) · Cyclophosphamide (62) · Cisplatin (61) · liposomal doxorubicin (59) · pembrolizumab (57) · olaparib (51) · niraparib (43) · Docetaxel (39) · Filgrastim (38) · Etoposide (30) · Drug Therapy (28)
Memorial Sloan Kettering Cancer Center (75) · National Cancer Institute (NCI) (47) · Gynecologic Oncology Group (43) · M.D. Anderson Cancer Center (42) · AstraZeneca (32) · Dana-Farber Cancer Institute (31) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (27) · Masonic Cancer Center, University of Minnesota (24) · Eli Lilly and Company (18) · ARCAGY/ GINECO GROUP (16) · Hoffmann-La Roche (15) · University Health Network, Toronto (15) · AGO Study Group (14) · European Organisation for Research and Treatment of Cancer - EORTC (14) · NYU Langone Health (14)
United States (1075) · China (236) · United Kingdom (187) · France (165) · Canada (160) · Italy (160) · Spain (141) · Belgium (108) · Australia (104) · Germany (104) · South Korea (86) · Netherlands (75) · Denmark (69) · Japan (54) · Poland (54)
Paul Sabbatini, MD (12) · Franco Muggia, MD (7) · Francesco Perrone, M.D., Ph.D. (6) · Jalid Sehouli (6) · Peter G. Rose, MD (6) · Sandro Pignata, M.D., Ph.D. (6) · Amit Oza, M.D. (5)
PMID 37185961, PMID 37407274, PMID 35170751, PMID 30633128, PMID 16394300, PMID 20818904, PMID 29342393, PMID 35397664, PMID 35537408, PMID 12826431, PMID 16882940, PMID 16966687, PMID 17949799, PMID 19238149, PMID 19282241, PMID 19427025, PMID 21941283, PMID 24637997, PMID 26707054, PMID 28935273, PMID 31685558, PMID 36459691, PMID 36718018, PMID 39123210, PMID 39695768, PMID 40443562, PMID 10481771, PMID 11165129, PMID 11181662, PMID 11410496, PMID 11704843, PMID 11705489, PMID 11870167, PMID 11919245, PMID 12065559, PMID 12082455, PMID 12082456, PMID 12114401, PMID 12528778, PMID 12586591, PMID 12694666, PMID 12713990, PMID 12829663, PMID 12893206, PMID 12957454, PMID 14534883, PMID 14615449, PMID 14645425, PMID 14656276, PMID 14701774
2023 (14), 2018 (13), 2008 (11), 2025 (11), 2017 (9), 2009 (8), 2016 (8), 2015 (7), P30CA008748 (7), P30CA033572 (7), U10CA032102 (7), P30CA043703 (6), P30CA015083 (5), P30CA068485 (5), 2019 (4)